- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Administration Will Crack Down on ACA Deadlines
What we're reading, February 25, 2016: the government will require proof of eligibility for enrollment in special sign-up periods under the Affordable Care Act (ACA); this year's flu vaccine is more effective; and 6 states are suing the Obama administration over an ACA fee.
The Obama administration will require customers prove their eligibility for special enrollment periods under the Affordable Care Act (ACA), according to The Hill. Insurers had cited concerns that a lack of verification was leading some to sign up only when they got sick. In January, the administration also announced it would reduce the number of special sign-up periods.
This year’s flu vaccine is a better match for the strains making people sick, which means it is more effective compared with last year’s vaccine. Data show that the vaccine is 59% effective, which is far better than the vaccine that was less than 20% effective last flu season, reported AP. While this flu season has been milder, health officials say it has not peaked yet.
Six states are suing the Obama administration over a fee to cover the federal subsidies under the ACA. Texas, Wisconsin, Kansas, Louisiana, Indiana, and Nebraska are arguing that the healthcare law did not make it clear that states would have to pay the fee in addition to health insurers, reported The New York Times. The suit asks that the states be refunded what they already paid.
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
January 18th 2025The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Read More
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
